human
-
DATABASE (43)
-
ARTICLES (158)
China’s first developer of self-driving robots, Zhen Robotics aims to revolutionize last-mile delivery.
China’s first developer of self-driving robots, Zhen Robotics aims to revolutionize last-mile delivery.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
CTO and Co-founder of Codemao (Bianchengmao)
Sun received his bachelor's in Electrical, Electronics and Communications Engineering at Beijing University of Post and Telecommunications. In 2012, he and future co-founder of Codemao Li Tianchi both began a European master's program in Human Computer Interaction. Sun worked with Li and other students to build a software called Settler in 2013, which helped international students studying in France find banks, apartments, etc. Both Sun and Li were kicked out of the startup due to differences of opinion. In 2014, just months before Sun would have graduated in 2015, he quit the program, giving up three degrees, returned to China and founded Codemao with Li.
Sun received his bachelor's in Electrical, Electronics and Communications Engineering at Beijing University of Post and Telecommunications. In 2012, he and future co-founder of Codemao Li Tianchi both began a European master's program in Human Computer Interaction. Sun worked with Li and other students to build a software called Settler in 2013, which helped international students studying in France find banks, apartments, etc. Both Sun and Li were kicked out of the startup due to differences of opinion. In 2014, just months before Sun would have graduated in 2015, he quit the program, giving up three degrees, returned to China and founded Codemao with Li.
Co-founder and COO of Line Health
Former journalist Sofia Simões de Almeida graduated from New University of Lisbon with degrees in Law and Communication Sciences. In 2010, she became a founding member and editor at Lead Magazine. After working at Human Resources Portugal in Lisbon, she founded HR startup "Make it Happy" in 2012 that was incubated at Startup Lisboa.In 2014, she co-founded Line Health and worked at the healthtech as COO until the company was closed down in 2018. Currently based in Berlin, she is now the head of Feed Rocket, an online marketing tool launched by Visual Meta Business Labs.
Former journalist Sofia Simões de Almeida graduated from New University of Lisbon with degrees in Law and Communication Sciences. In 2010, she became a founding member and editor at Lead Magazine. After working at Human Resources Portugal in Lisbon, she founded HR startup "Make it Happy" in 2012 that was incubated at Startup Lisboa.In 2014, she co-founded Line Health and worked at the healthtech as COO until the company was closed down in 2018. Currently based in Berlin, she is now the head of Feed Rocket, an online marketing tool launched by Visual Meta Business Labs.
Co-founder, COO of Kibus Petcare
Marta Arisa is co-founder and COO at Kibus Petcare, the first hardware that automatically cooks and dispenses healthy pet food. She has worked there since 2018. She simultaneously continues to work at the Catalan Tourist Board, where she is currently budget manager. Prior to this, she worked in human resources at Innova Humana Consultores for one and a half years and for two years in business support at the Polytechnic University of Catalonia's corporate innovation program Innova. She also briefly worked as a consultant at the business transfer Marketplace for SMEs in Catalonia.Arisa holds a Master's degree in Financial Management and Accounting from Barcelona's Pompeu Fabra University.
Marta Arisa is co-founder and COO at Kibus Petcare, the first hardware that automatically cooks and dispenses healthy pet food. She has worked there since 2018. She simultaneously continues to work at the Catalan Tourist Board, where she is currently budget manager. Prior to this, she worked in human resources at Innova Humana Consultores for one and a half years and for two years in business support at the Polytechnic University of Catalonia's corporate innovation program Innova. She also briefly worked as a consultant at the business transfer Marketplace for SMEs in Catalonia.Arisa holds a Master's degree in Financial Management and Accounting from Barcelona's Pompeu Fabra University.
Feedzai is a powerful cloud-based AI tool detecting e-commerce fraud in real-time among trillions of dollars of transactions by the world’s largest corporates.
Feedzai is a powerful cloud-based AI tool detecting e-commerce fraud in real-time among trillions of dollars of transactions by the world’s largest corporates.
CTO and co-founder of The Not Company (NotCo)
Karim Pichara has a PhD in Computer Science from the Catholic University of Chile where he has been working for over 10 years since 2010. From 2011, Karim Pichara has also been working as a research associate at the Institute of Applied Computer Science, Harvard University, specializing in data mining and machine learning for astronomy. In November 2015, while at Harvard, Pichara and Matías Muchnick co-founded a plant-based foodtech, The Not Company (NotCo). Pichara became the CTO and headed the development of NotCo’s algorithm called “Giuseppe” that can analyze molecular structures of animal-based food to create similar plant-based food that cater to the human perception of taste and texture.
Karim Pichara has a PhD in Computer Science from the Catholic University of Chile where he has been working for over 10 years since 2010. From 2011, Karim Pichara has also been working as a research associate at the Institute of Applied Computer Science, Harvard University, specializing in data mining and machine learning for astronomy. In November 2015, while at Harvard, Pichara and Matías Muchnick co-founded a plant-based foodtech, The Not Company (NotCo). Pichara became the CTO and headed the development of NotCo’s algorithm called “Giuseppe” that can analyze molecular structures of animal-based food to create similar plant-based food that cater to the human perception of taste and texture.
Founded and headed by Susan Choe in 2018, Katalyst Ventures is based in San Francisco with a debut fund of $34m raised in 2018. Choe is also a partner at another Zipline investor Visionnaire Ventures (VV) also based in Silicon Valley. Katalyst invests in seed and early-stage tech startups with human-centric solutions. About 45% of the VC funds are invested in startups with women as CEO or CTO. By February 2020, the Kalatyst portfolio included 22 enterprises and three exits.The founder of Outspark was removed as CEO by the board of directors due to disagreements over the sale of Outspark. She had used her own money in 2006 to create Outspark, a data-driven publishing platform for game developers. Outspark was eventually sold to Axel Springer and Choe went left the company to join Taizo Son’s venture capital group. In 2013, VV was set up to support tech startups in the US. Choe had worked for Yahoo! and also was the COO of the public-listed holding company of South Korean search and media company NHN.
Founded and headed by Susan Choe in 2018, Katalyst Ventures is based in San Francisco with a debut fund of $34m raised in 2018. Choe is also a partner at another Zipline investor Visionnaire Ventures (VV) also based in Silicon Valley. Katalyst invests in seed and early-stage tech startups with human-centric solutions. About 45% of the VC funds are invested in startups with women as CEO or CTO. By February 2020, the Kalatyst portfolio included 22 enterprises and three exits.The founder of Outspark was removed as CEO by the board of directors due to disagreements over the sale of Outspark. She had used her own money in 2006 to create Outspark, a data-driven publishing platform for game developers. Outspark was eventually sold to Axel Springer and Choe went left the company to join Taizo Son’s venture capital group. In 2013, VV was set up to support tech startups in the US. Choe had worked for Yahoo! and also was the COO of the public-listed holding company of South Korean search and media company NHN.
TurtleTree Labs will license its technology for creating natural ingredients found in human milk to dairy and infant formula companies to produce full-composition liquid milk.
TurtleTree Labs will license its technology for creating natural ingredients found in human milk to dairy and infant formula companies to produce full-composition liquid milk.
Co-founder of AllRead MLT
Dimosthenis Karatzas is Senior Research Fellow and Associate Director at the Computer Vision Centre (CVC) of the Autonomous University of Barcelona (UAB). He specializes in computer vision, document image analysis and color science. In 2007, he co-founded TruColour in the UK, where he currently is a member of the board of directors. In 2013, he was awarded the IAPR/ICDAR Young Investigator Award “for outstanding service and innovative research in human perception-based document analysis.” Karatzas also worked as a Research Fellow at the University of Liverpool and University of Southampton in the UK. Since 2019, he has been part of the co-founding team of Allread MLT, a deep-tech startup that converts text, symbols and codes to Big Data using computer vision technology, character recognition and machine learning.
Dimosthenis Karatzas is Senior Research Fellow and Associate Director at the Computer Vision Centre (CVC) of the Autonomous University of Barcelona (UAB). He specializes in computer vision, document image analysis and color science. In 2007, he co-founded TruColour in the UK, where he currently is a member of the board of directors. In 2013, he was awarded the IAPR/ICDAR Young Investigator Award “for outstanding service and innovative research in human perception-based document analysis.” Karatzas also worked as a Research Fellow at the University of Liverpool and University of Southampton in the UK. Since 2019, he has been part of the co-founding team of Allread MLT, a deep-tech startup that converts text, symbols and codes to Big Data using computer vision technology, character recognition and machine learning.
CEO and Founder of CH Biomedical
Chen Chen is an expert in artificial heart development. After graduating from Tsinghua University with a major in Thermal Engineering in 1984, he switched to study Biomechanics in Sichuan University and received a doctorate in 1991.He lectured at Nanjing University from 1991 to 1996 before going to Japan to continue his research on artificial heart technology and development. He was a visiting scholar at the University of Tokyo for one year until 1997.In 1999, Chen was headhunted and joined a US startup to work on developing an artificial heart (LVAD) product Levacor. The startup was later acquired by World Heart Corporation and Chen became its chief engineer. World Heart decided to shut down the program in 2006 because the product was too big to be placed inside a human chest.Chen went back to China in 2007 to found CH Biomedical to build a smaller LVAD device.
Chen Chen is an expert in artificial heart development. After graduating from Tsinghua University with a major in Thermal Engineering in 1984, he switched to study Biomechanics in Sichuan University and received a doctorate in 1991.He lectured at Nanjing University from 1991 to 1996 before going to Japan to continue his research on artificial heart technology and development. He was a visiting scholar at the University of Tokyo for one year until 1997.In 1999, Chen was headhunted and joined a US startup to work on developing an artificial heart (LVAD) product Levacor. The startup was later acquired by World Heart Corporation and Chen became its chief engineer. World Heart decided to shut down the program in 2006 because the product was too big to be placed inside a human chest.Chen went back to China in 2007 to found CH Biomedical to build a smaller LVAD device.
Early-stage-focused VC firm with a €24m first fund mainly investing in B2B and B2C digital startups headquartered in Spain. Initial investment amounts range between €70,000 and €300,000, and followup investment amounts go up to €1m per company. Describing themselves as “momentum investors” seeking quick time-to-market projects, Encomenda Smart Capital was founded in 2017 and managed by renowned Spanish angel investors Carlos Blanco, Oriol Juncosa and Miguel Sanz Sanchez, along with a network of angel investors Encomenda supports the growth of startups' portfolios and helps startups to scale at national and international levels. Encomenda invests 30% in SaaS and in projects with a recurring income model; 20% are fintech, and they also bet on the human resources, edtech and healthcare. Just two out of 25 investments have folded up between 2017 and 2020, with half the fund monies committed. Encomenda is seeking to launch a second fund in 2022 focusing on Spanish and Portuguese startups, of €40m–€50m, and multi-stage, by starting in the early-stage investments, with follow-through investments in subsequent stages.
Early-stage-focused VC firm with a €24m first fund mainly investing in B2B and B2C digital startups headquartered in Spain. Initial investment amounts range between €70,000 and €300,000, and followup investment amounts go up to €1m per company. Describing themselves as “momentum investors” seeking quick time-to-market projects, Encomenda Smart Capital was founded in 2017 and managed by renowned Spanish angel investors Carlos Blanco, Oriol Juncosa and Miguel Sanz Sanchez, along with a network of angel investors Encomenda supports the growth of startups' portfolios and helps startups to scale at national and international levels. Encomenda invests 30% in SaaS and in projects with a recurring income model; 20% are fintech, and they also bet on the human resources, edtech and healthcare. Just two out of 25 investments have folded up between 2017 and 2020, with half the fund monies committed. Encomenda is seeking to launch a second fund in 2022 focusing on Spanish and Portuguese startups, of €40m–€50m, and multi-stage, by starting in the early-stage investments, with follow-through investments in subsequent stages.
Co-founder of Meatable
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
IONIC AI: Human-centric technology that enhances mobile phone performance
Giving new life to old mobile phones and upgrading cheaper ones, IONIC AI's tech also keeps gamers' phones cool for longer usage
Nutrinsect: Aiming at insects for human consumption for the planet's sake
Nutrinsect expects insect-based foodstuffs to supplement meat to satisfy the ever-growing hunger for protein
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
Atomian: The powerful cognitive software that thinks, works like the human brain
Combining natural language processing with big data, Atomian enables easy, quick and real-time access to information in databases and documents
Triporate: Producing business travel itineraries and bookings 10x faster than human agents
Triporate helps corporates save time and money with its automated travel bookings from analyzing staff emails; it raised €1.3m recently
Fumi Technology: Getting ahead of human wealth managers with its Webull robo-advisors
Fumi's AI-based fintech platform offers real-time quotes and free trading to over 10m punters in 100 countries
TurtleTree Labs: Creating sustainable mammalian milk alternatives from stem cells
Founder’s search for high-quality dairy milk led to the creation in a lab of naturally occurring ingredients found in human milk for supply to dairy milk and infant formula businesses
Biomilq: Creating cell-based mothers’ milk in a lab
With the aim of helping women struggling to breastfeed, Bill Gates-backed Biomilq is disrupting the $45bn baby formula industry developing lab-grown breast milk from mammary epithelial cells
Dorabot's aim for warehousing: No humans allowed
With a combination of AI, global partnerships and speed, Dorabot is leaping into the future
Feedect provides nutritional insect protein to feed the future
Feedect farms insects to produce high-quality protein alternatives for animal and human food
An AI future as seen through Chinese retail
Retail provides a good contemporary case study for how an AI future might look in China
BioMind: AI medical diagnostics with over 90% accuracy for 100 diseases
BioMind helps doctors save lives by providing more accurate diagnosis of life-threatening diseases like Covid-19 and brain tumors
Squirrel AI: Edtech's AI-based personalized tutoring eases load for students and teachers
Used by more than 3m students, unicorn Squirrel AI tracks learning outcomes in real time and adapts teaching, proving more effective than traditional methods
After insurtech and fintech, Newralers applies AI to winemaking
Newralers expects strong demand for its disruptive AI solutions that test the cognitive value of information, with clients from listed companies to SMEs
Didimo: Creator of "digital humans" secures €6.2m in seed funding
Portuguese startup Didimo aims to humanize online interactions with its disruptive 3D technology
Sorry, we couldn’t find any matches for“human”.
POPULAR DATABASE
